CharlesMFarberMD

Oncology • Morristown, NJ

Hematologic Oncology

Assistant Clinical Professor of Medicine, UMDNJ - New Jersey Medical School Newark

Join to view full profile

Dr. Farber is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Farber's full profile

Already have an account?

Office
100 Madison Avenue
Carol G Simon Cancer Center
Morristown, NJ 07960

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1988 - 1992
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1986 - 1988
New York University School of MedicineClass of 1986

Certifications & Licensure

NJ State Medical License 1995 - 2025
FL State Medical License 2015 - 2021
NY State Medical License 1987 - 1996
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Hematology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology

Awards, Honors, & Recognition

Inside Jersey Top Doctors for Cancer Castle Connolly, 2012-2014
Inside Jersey Magazine Top Doctors Castle Connolly, 2010-2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
Inside Jersey - Top Doctors for Women's Health Castle Connolly, 2010-2012
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
NJ.com Top Doctors Castle Connolly, 2009
Join now to see all

Clinical Trials

Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
Completed
Phase 2
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
Completed
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
Completed
Phase 3
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2013 May 01
Completed
Phase 1
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma Start of enrollment: 2015 Oct 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States.
Jorge J Castillo, Edwin C Kingsley, Mohit Narang, Habte A Yimer, Constantin A Dasanu
Ejhaem. 2023-02-01
14 citations
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites
Anthony R. Mato, Chadi Nabhan, Nicole Lamanna, Neil E. Kay, David L. Grinblatt
Blood Advances. 2020-04-14
57 citations
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200
Daruka Mahadevan, Mark C. Lanasa, Charles M. Farber, Manjari Pandey, Maria Whelden
Journal for Immunotherapy of Cancer. 2019-08-23

Lectures

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

New Jersey’s Only Site for Study of Waldenstrӧm Macroglobulinemia (A Rare Non-Hodgkin Lymphoma) Open at Morristown Medical CenterMarch 15th, 2020
Atlantic Health System Adds Two Established Doctors to Lead New Initiatives in Hematology OncologyApril 21st, 2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member